NeuroPace Q3 revenue misses analyst estimates, dragged by account-level issues

By Reuters News


Overview

  • U.S. epilepsy device maker's Q3 revenue declined 1% yr/yr, missing analyst expectations

  • Company narrowed Q3 net loss compared to prior year

  • NeuroPace cut full-year 2026 revenue guidance, citing account-level disruptions and field changes


Outlook

  • NeuroPace cuts 2026 revenue guidance to $91 mln-$92 mln from $99.5 mln-$101.5 mln

  • Company raises 2026 non-GAAP gross margin outlook to 83.0%-83.5% from 82.0%-83.0%

  • NeuroPace lowers 2026 non-GAAP operating expense forecast to $85 mln-$86 mln from $90 mln-$92 mln


Result Drivers

  • ACCOUNT-LEVEL DISRUPTIONS - Co said Q3 revenue shortfall was concentrated in several large accounts and reflected isolated account-level issues and field organization changes

  • COMMERCIAL EXECUTION - Co said it is taking action to improve commercial execution and return to historical growth rates

  • LOWER PERSONNEL COSTS - Decline in operating expenses was largely due to decreased personnel-related expenses, including sales commissions and variable compensation


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

$23.10 mln

$27.16 mln (10 Analysts)

Q3 Loss Per Share

$0.10

Q3 Net Loss

$3.30 mln

Q3 Gross Profit

$19.47 mln

Q3 Operating Expenses

$21.55 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for NeuroPace, Inc. is $20.00, about 59.7% above its November 11 closing price of $12.52


Reuters Recommended Reads

  • Nov 10 - Switzerland's Alcon Q3 sales slightly miss estimates despite surgical equipment launches, vision care growth

  • Nov 10 - Surgical robotics firm Stereotaxis' Q3 revenue rises, but misses estimates

  • Nov 10 - QT Imaging Q3 revenue jumps 75% on scanner sales


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk